A Look Back: Why California's Stem Cell Royalties are Relatively Skimpy
Editor’s Note: The following piece first appeared March 8, 2020, on the California Stem Cell Report and provides a look at the intellectual property rules at the California Institute for Regenerative Medicine (CIRM).
Inside California Stem Cell IP: A Look at the Royalty Money Trail
The $4.9 billion purchase of a California immunology firm is a rich deal f…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.